Ironwood Pharmaceuticals, Inc. revised earnings guidance for its Fiscal Year 2024. Total Revenue reported its Prior 2024 Guidance of $435 to $455 million as compared to Revised 2024 Guidance of revenue to be $405 to $425 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.95 USD | -1.82% | -8.18% | -47.99% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.99% | 946M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- IRWD Stock
- News Ironwood Pharmaceuticals, Inc.
- Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024